Antisuicidal Effects in Mood Disorders: Are They Unique to Lithium?

Abstract

Introduction Suicidal behavior is strongly associated with depression in major depressive (MDD) and bipolar (BD) disorders, especially with associated behavioral activation, dysphoria, or agitation. A rare intervention with evidence of suicide risk-reducing as well as mood-stabilizing effects in mood disorder patients is lithium.

Methods We reviewed available research evidence on associations of long-term treatment with lithium with risk of suicidal behavior. We meta-analyzed 12 randomized trials in 10 reports (with at least 1 suicide in either treatment arm) including both BD and MDD subjects, with particular attention to comparisons of lithium with placebo or other pharmacological treatments. We also summarized ecological studies on lithium concentration in local drinking water and reported suicide rates.

Results We found substantial reduction of risks of suicide and attempts with long-term lithium treatment, particularly in depressive phases of BD and in MDD. Risk of suicidal behavior was higher in mixed (agitated-dysphoric) states than in manic or hypomanic periods. Risk of suicide fatality, specifically, was lower with lithium than with placebo and probably with mood-altering anticonvulsants or antidepressants.

Discussion Long-term treatment with lithium has growing evidence of suicide- and attempt-sparing effects, probably greater than with anticonvulsants or antidepressants; antipsychotics remain to be tested adequately. However, the ethical and scientifically adequate design and conduct of trials of treatments aimed at suicide prevention remain challenging and underdeveloped.

Key words

anticonvulsants - antidepressants - antipsychotics - bipolar I and II disorders - lithium - major depressive disorder - suicide

• References

• 1 Ahrens B, Müller-Oerlinghausen B, Schou M. et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 1995; 33: 67-75
• 2 Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992; 25: 261-269
• 3 Tondo L, Jamison KR, Baldessarini RJ. Effect of lithium maintenance on suicidal behavior in major mood disorders. Ann N Y Acad Sci 1997; 836: 339-351
• 4 Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: A meta-analysis. Schizophr Res 2005; 73: 139-145
• 5 Meltzer HY, Alphs L, Green AI. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91
• 6 World Health Organization (WHO). Suicide Rates Age-Standardized by Country. 2015; Accessed at: http://apps.who.int/gho/data/view.main.MHSUICIDEREGv?lang = en Accessed on: December 13, 2017
• 7 Harris EC, Barraclough B. Excess mortality of mental disorder. Brit J Psychiatry 1998; 173: 11-53
• 8 Schaffer A, Isometsä ET, Tondo L. et al. Epidemiology neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disord Task Force on Suicide in Bipolar Disorder. ANZJP 2015; 49: 785-802
• 9 Tondo L, Pompili M, Forte A. et al. Suicide attempts in bipolar disorders: Comprehensive review of 101 reports. Acta Psychiatr Scand 2016; 133: 174-186
• 10 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-5. 5th ed. Washington, DC: APA; 2013
• 11 Swann AC, Lafer B, Perugi G. et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure course of illness and diagnosis. Am J Psychiatry 2013; 170: 31-42
• 12 Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: A review and meta-analysis of the evidence. Bipolar Disord 2010; 12: 1-9
• 13 Baldessarini RJ. ed. Chemotherapy in Psychiatry. New York: Springer; 2013
• 14 Baldessarini RJ, Vieta E. Calabrese JR, et al. Bipolar depression: Overview and commentary. Harv Rev Psychiatry 2010; 18: 143-157
• 15 Baldessarini RJ, Faedda GL, Offidani E. et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: A review. J Affect Disord 2013; 148: 129-135
• 16 Faedda GL, Marangoni C, Serra G. et al. Precursors of bipolar disorders: A systematic literature review of prospective studies. J Clin Psychiatry 2015; 76: 614-624
• 17 Koukopoulos A, Sani G, Koukopoulos AE. et al. Melancholia agitata and mixed depression. Acta Psychiatr Scand 2007; 115: 50-57
• 18 Koukopoulos A, Reginaldi D, Tondo L. et al. Course sequences in bipolar disorder: Depressions preceding or following manias or hypomanias. J Affect Disord 2013; 151: 105-110
• 19 Pacchiarotti I, Bond DJ, Baldessarini RJ. et al. The International Society for Bipolar Disorder (ISBD) task force report on antidepressant use in bipolar disorder. Am J Psychiatry 2013; 170: 1249-1262
• 20 Vázquez GH, Tondo L, Undurraga J. et al. Overview of antidepressant treatment of bipolar depression. Int J Neuropsychopharmacol 2013; 16: 1673-1685
• 21 Vázquez GH, Tondo L, Undurraga J. et al. Pharmacological treatment of bipolar depression. Advan Psychiatr Treat 2014; 20: 193-201
• 22 De Dios C, Ezquiaga E, Garcia A. et al. Time spent with symptoms in a cohort of bipolar disorder outpatients in Spain: A prospective 18-month follow-up study. J Affect Disord 2010; 125: 74-81
• 23 Forte A, Baldessarini RJ, Tondo L. et al. Long-term morbidity in bipolar-I bipolar-II and unipolar major depressive disorders. J Affect Disord 2015; 178: 71-78
• 24 Vázquez GH, Lolich M, Cabrera C. et al. Mixed symptoms in major depressive and bipolar disorders: A systematic review. J Affect Disord 2018; 225: 756-760
• 25 Goldsmith S, Pellmar T, Kleinman A, Bunney WE. eds. Reducing Suicide: A National Imperative. Washington, DC: National Academies Press; 2002
• 26 Jacobs D, Brewer M. APA practice guideline provides recommendations for assessing and treating patients with suicidal behaviors. Psychiatr Ann 2004; 34: 373-380
• 27 Tondo L, Baldessarini RJ. Reduction of suicidal behavior in bipolar disorder patients during long-term treatment with lithium. In: Koslow S, Ruiz P, Nemeroff C. eds. A Concise Guide to Understanding Suicide. Cambridge, UK: Cambridge University Press; 2014: 217-218
• 28 Tondo L, Baldessarini RJ. Suicide in bipolar disorder. In: Yildiz A, Nemeroff C, Ruiz P. eds. The Bipolar Book: History, Neurobiology and Treatment. New York: Oxford University Press; 2015: 509-528
• 29 Weinger R. ed. Practice of Electroconvulsive Therapy: Recommendations for Treatment Training and Privileging. Task Force Report of the American Psychiatric Association. 2nd ed. Washington, DC: American Psychiatric Press; 2002
• 30 Sareen J, Isaak C, Katz LY. et al. Promising strategies for advancement in knowledge of suicide risk factors and prevention. Am J Prev Med 2014; 47: S257-S263
• 31 Sheehan D, Giddens J. eds. Suicidality: A Roadmap for Assessment Treatment. Tampa, FL: Harm Research Press; 2015
• 32 Brenner LA, Breshears RE, Betthauser LM. et al. Implementation of a suicide nomenclature within two VA healthcare settings. J Clin Psychol Med Settings 2011; 18: 116-128
• 33 Crosby A, Ortega L, Melanson C. Self-Directed Violence Surveillance: Uniform Definitions and Recommended Data Elements Version 10 Atlanta: Centers for Disease Control and Prevention National Center for Injury Prevention and Control Division of Violence Prevention; 2011. Accessed at: https://www.cdc.gov/violenceprevention/pdf/self-directed-violence-a.pdf Accessed on: December 13, 2017
• 34 U.S. Food and Drug Administration. Guidance for Industry Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2012. Accessed at: https://www.fda.gov/downloads/drugs/guidances/ucm225130.pdf
• 35 Cipriani A, Hawton K, Stockton S. Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ 2013; 346: f3646
• 36 Smith KA, Cipriani A. Lithium and suicide in mood disorders: Updated meta-review of the scientific literature. Bipolar Disord 2017; 19: 575-586
• 37 Baldessarini RJ, Tondo L, Davis P. et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8: 625-639
• 38 Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: A meta-analysis. Acta Psychiatr Scand 2001; 104: 163-172
• 39 Bauer M, Bschor T, Kunz D. et al. Double-blind placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157: 1429-1435
• 40 Calabrese JR, Bowden CL, Sachs G. et al Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024
• 41 Glen AI, Johnson AL, Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: A randomized double-blind controlled trial. Psychol Med 1984; 14: 37-50
• 42 Greil W, Ludwig-Mayerhofer W, Erazo N. et al. Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: A randomised study. J Affect Disord 1996; 40: 179-190
• 43 Greil W, Ludwig-Mayerhofer W, Erazo N. et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders–a randomised study. J Affect Disord 1997; 43: 151-161
• 44 Lauterbach E, Felber W, Müller-Oerlinghausen B. et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: A randomised placebo-controlled 1-year trial. Acta Psychiatr Scand 2008; 118: 469-479
• 45 Licht RW, Nielsen JN, Gram LF. et al. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: An open randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 12: 483-493
• 46 Prien RF, Klett CJ, Caffey EM. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry 1973; 29: 420-425
• 47 Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W. et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Pharmacopsychiatry 1996; 29: 103-107
• 48 Tohen M, Greil W, Calabrese JR. et al Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month randomized double-blind controlled clinical trial. Am J Psychiatry 2005; 162: 1281-1290
• 49 Vita A, De Peri L, Sacchetti E. Lithium in drinking water and suicide prevention. Int Clin Psychopharmacol 2015; 30: 1-5
• 50 Baldessarini RJ, Tondo L. Lithium and suicidal risk. Bipolar Disord 2008; 10: 114-115
• 51 Guzzetta F, Tondo L, Centorrino F. et al. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007; 68: 380-383
• 52 Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol Psichiatr Soc 2009; 18: 179-183
• 53 Blüml V, Regier MD, Hlavin G. et al. Lithium in the public water supply and suicide mortality in Texas. J Psychiatr Res 2013; 47: 407-411
• 54 Dawson EB, Moore TD, McGanity WJ. Relationship of lithium metabolism to mental hospital admission and homicide. Dis Nerv Sys 1972; 33: 546-556
• 55 Giotakos O, Tsouvelas G, Nisianakis P. et al. Negative association between lithium in drinking water and the Incidences of homicides in Greece. Biol Trace Elem Res 2015; 164: 165-168
• 56 Giotakos O, Nisianakis P, Tsouvelas G. Lithium in the public water supply and suicide mortality in Greece. Biol Trace Elem Res 2013; 156: 376-379
• 57 Helbich M, Leitner M, Kapusta ND. Lithium in drinking water and suicide mortality: interplay with lithium prescriptions. Brit J Psychiatry 2015; 207: 64-71
• 58 Helbich M, Blüml V, Leitner M. et al. Does altitude moderate the impact of lithium on suicide? A spatial analysis of Austria. Geospat Health 2013; 7: 209-218
• 59 Helbich M, Leitner M, Kapusta ND. Geospatial examination of lithium in drinking water and suicide mortality. Int J Health Geograph 2012; 11: 19
• 60 Ishii N, Terao T, Araki Y. et al. Low risk of male suicide and lithium in drinking water. J Clin Psychiatry 2015; 76: 319-326
• 61 Kabacs N, Memon A, Obinwa T. et al. Lithium in drinking water and suicide rates across the East of England. Brit J Psychiatry 2011; 198: 406-407
• 62 Kapusta ND, Mossaheb N, Etzersdorfer E. et al. Lithium in drinking water and suicide mortality. Brit J Psychiatry 2011; 198: 346-350
• 63 Knudsen NN, Schullehner J, Hansen B. et al. Lithium in drinking water and incidence of suicide: a nationwide individual-level cohort study with 22 years of follow-up. Int J Environ Res Pub Health 2017; 14: 627-640
• 64 König D, Baumgartner J, Blüml V. et al. [Impact of natural lithium resources on suicide mortality in Chile 2000–2009: A geographical analysis]. Neuropsychiatrie 2017; 31: 70-76
• 65 Liaugaudaite V, Mickuviene N, Raskauskiene N. et al. Lithium levels in the public drinking water supply and risk of suicide: a pilot study. J Trace Elem Med Biol 2017; 43: 197-201
• 66 Ohgami H, Terao T, Shiotsuki I. et al. Lithium levels in drinking water and risk of suicide. Brit J Psychiatry 2009; 194: 464-465
• 67 Pompili M, Vichi M, Dinelli E. et al. Relationships of local lithium concentrations in drinking water to regional suicide rates in Italy. World J Biol Psychiatry 2015; 16: 567-574
• 68 Schrauzer GN, Shrestha KP. Lithium in drinking water and the incidences of crimes suicides and arrests related to drug addictions. Biol Trace Elem Res 1990; 25: 105-113
• 69 Shiotsuki I, Terao T, Ishii N. et al. Trace lithium is inversely associated with male suicide after adjustment of climatic factors. J Affect Disord 2016; 189: 282-286
• 70 Sugawara N, Yasui-Furukori N, Ishii N. et al. Lithium in tap water and suicide mortality in Japan. Int J Environ Res Pub Health 2013; 10: 6044-6048
• 71 Hayes JF, Marston L, Walters K. et al. Lithium vs valproate vs olanzapine vs quetiapine as maintenance monotherapy for bipolar disorder: A population-based UK cohort study using electronic health records. World Psychiatry 2016; 15: 53-85
• 72 Hayes JF, Pitman A, Marston L. et al. Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment a UK population-based electronic health records study. JAMA Psychiatry 2016; 73: 630-637
• 73 Oquendo M, Hanga M, Galfalvy C. et al. Treatment of suicide attempters with bipolar disorder: Randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry 2011; 168: 1050-1056
• 74 Søndergård L, Lopez AG, Andersen PK. et al. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord 2008; 10: 87-94
• 75 Baldessarini R, Tondo L. Suicidal risks during treatment of bipolar disorder patients with lithium vs anticonvulsants. Pharmacopsychiatry 2009; 42: 72-75
• 76 U.S. Food and Drug Administration. Statistical Review and Evaluation: Antiepileptic Drugs and suicidality; 2008. Accessed at: https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm192556.pdf Accessed on: December 15, 2017
• 77 Goodwin FK, Fireman B, Simon GE. et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467-1473
• 78 Posner K, Oquendo MA, Gould M. et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007; 164: 1035-1043
• 79 Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior: Lithium, divalproex and carbamazepine. J Affect Disord 2007; 103: 5-11
• 80 Smith EG, Søndergård L, Lopez AG. et al. Association between consistent purchase of anticonvulsants or lithium and suicide risk: A longitudinal cohort study from Denmark 1995–2001. J Affect Disord 2009; 117: 162-167
• 81 Fountoulakis KN, Gonda X, Baghai TC. et al. Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. Int J Psychiatry Clin Pract 2015; 19: 158-167
• 82 Gibbons RD, Hur K, Brown CH. et al. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009; 66: 1354-1360
• 83 Smith EG, Austin KL, Kim M. et al. Suicide risk in Veterans Health Administration patients with mental health diagnoses initiating lithium or valproate: historical prospective cohort study. BMC Psychiatry 2014; 14: 357
• 84 Ferrer P, Ballarín E, Sabaté M. et al. Antiepileptic drugs and suicide: Systematic review of adverse effects. Neuroepidemiol 2014; 42: 107-120
• 85 Mula M, Sander JW. Suicide risk in people with epilepsy taking antiepileptic drugs. Bipolar Disord 2013; 15: 622-627
• 86 Siamouli M, Samara M, Fountoulakis KN. Is antiepileptic-induced suicidality a data-based class effect or an exaggeration? A comment on the literature. Harv Rev Psychiatry 2014; 22: 379-381
• 87 Akiskal HS, Benazzi F, Perugi G. et al. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord 2005; 85: 245-258
• 88 Sim K, Lau WK, Sim J. et al. Prevention of relapse and recurrence in adults with major depressive disorder: Systematic review and meta-analyses of controlled trials. Intl J Neuropsychopharmacol 2015; 19: 1-13
• 89 Søndergård L, Kvist K, Lopez A. et al. Temporal changes in suicide rates for persons treated and not treated with antidepressants in Denmark during 1995–1999. Acta Psychiatr Scand 2006; 114: 168-176
• 90 Tondo L, Isacsson G, Baldessarini R. Suicidal behavior in bipolar disorder: Risk and prevention. CNS Drugs 2003; 17: 491-511
• 91 Undurraga J, Baldessarini RJ. Randomized placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012; 37: 1-14
• 92 Yatham LN, Kennedy SH. Schaffer et al Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disord (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 2009; 11: 225-255
• 93 Jakobsen JC, Katakam KK, Schou A. et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry 2017; 17: 58-86
• 94 Ghaemi SN, Wingo AP, Filkowski MA. et al. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008; 118: 347-356
• 95 Vázquez G, Tondo L, Baldessarini RJ. Comparison of antidepressant responses in patients with bipolar vs unipolar depression: A meta-analytic review. Pharmacopsychiatry 2011; 44: 21-22
• 96 Tondo L, Baldessarini RJ, Vázquez G. et al. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr Scand 2013; 127: 355-364
• 97 El-Mallakh RS, Vöhringer PA, Ostacher MM. et al. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. J Affect Disord 2015; 184: 318-321
• 98 Baldessarini RJ, Lau WK, Sim J. et al. Suicidal risks in reports of long-term treatment trials for major depressive disorder. Int J Neuropsychopharmacol 2015; 19: pyv107
• 99 Bottlender R, Rudolf D, Strauss A. et al. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001; 63: 79-83
• 100 Braun C, Bschor T, Franklin J. et al. Suicides and suicide attempts during long-term treatment with antidepressants: meta-analysis of 29 placebo-controlled studies including 6,934 patients with major depressive disorder. Psychother Psychosom 2016; 85: 171-179
• 101 Gaertner I, Gilot C, Heidrich P. et al. A case-control study on psychopharmacotherapy before suicide committed by 61 psychiatric inpatients. Pharmacopsychiatry 2002; 35: 37-43
• 102 Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000; 57: 311-317
• 103 Laughren T. Overview of a Meeting of the Psychopharmacology Drug Advisory Committee (PDAC) Concerning Suicidal Risk in Trials of Antidepressant Drugs in Juvenile and Adult Patients; 2006 Accessed at: https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-fda.pdf Accessed on: February 5, 2018
• 104 Möller HJ. Antidepressants: Controversies about their efficacy in depression their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry 2009; 10: 180-195
• 105 Reseland S, Bray I, Gunnell D. Relationship between antidepressant sales and secular trends in suicide rates in the Nordic countries. Br J Psychiatry 2006; 188: 354-358
• 106 Valuck RJ, Libby AM, Anderson HD. et al. Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: Propensity matched retrospective cohort study. Br J Psychiatry 2016; 208: 271-279
• 107 Wise J. Antidepressants may double risk of suicide and aggression in children study finds. BMJ 2016; 352: i545
• 108 Yerevanian BI, Choi YM. Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disord 2013; 15: 594-621
• 109 Zisook S, Trivedi MH, Warden D. et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord 2009; 117: 63-73
• 110 Perugi G, Angst J, Azorin JM. et al. Mixed features in patients with a major depressive episode: The BRIDGE-II-MIX study. J Clin Psychiatry 2015; 76: e351-e358
• 111 Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006; 26: 203-207
• 112 Popovic D, Vieta E, Azorin JM. et al. Suicide attempts in major depressive episode: Evidence from the BRIDGE-II-Mix study. Bipolar Disord 2015; 17: 795-803
• 113 Tollefson GD, Rampey AH, Beasley CM. et al. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 1994; 14: 163-169
• 114 Baldessarini RJ, Tondo L, Strombom IM. et al. Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry 2007; 15: 133-145
• 115 Ghaemi SN, Hsu DJ, Soldani F. et al. Antidepressants in bipolar disorder: The case for caution. Bipolar Disord 2003; 5: 421-433
• 116 Stone MB. The FDA warning on antidepressants and suicidality: Why the controversy?. N Engl J Med 2014; 371: 1668-1671
• 117 Tondo L, Lepri B, Baldessarini RJ. Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder. Acta Psychiatr Scand 2008; 118: 106-151
• 118 Bridge J, Iyengar S, Salary CB. et al Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA 2007; 297: 1683-1696
• 119 Gibbons RD, Brown CH, Hur K. et al. Relationship between antidepressants and suicide attempts: An analysis of the Veterans Health Administration data sets. Am J Psychiatry 2007; 164: 1044-1049
• 120 Isacsson G, Holmgren A, Osby U. et al. Decrease in suicide among the individuals treated with antidepressants: A controlled study of antidepressants in suicide, Sweden 1995–2005. Acta Psychiatr Scand 2009; 120: 37-44
• 121 Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observational studies. CMAJ 2009; 180: 291-297
• 122 Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332-339
• 123 Selle V, Schalkwijk S, Vázquez GH. et al. Treatments for acute bipolar depression: meta-analyses of placebo-controlled monotherapy trials of anticonvulsants lithium and antipsychotics. Pharmacopsychiatry 2014; 47: 43-52
• 124 Vázquez GH, Holtzman JN, Tondo L. et al. Efficacy and tolerability of treatments for bipolar depression. J Affect Disord 2015; 183: 258-262
• 125 Tondo L, Albert MJ, Baldessarini RJ. Suicide rates in relation to health care access in the United States: An ecological study. J Clin Psychiatry 2006; 67: 517-523
• 126 Tiihonen J, Lönnqvist J, Wahlbeck K. et al. Eleven-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet 2009; 374: 620-627
• 127 Tiihonen J, Mittendorfer-Rutz E, Torniainen M. et al. Mortality and cumulative exposure to antipsychotics antidepressants and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 2016; 173: 600-606
• 128 Torniainen M, Mittendorfer-Rutz E, Tanskanen A. et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bullet 2015; 41: 656-663
• 129 Wimberley T, MacCabe JH, Laursen TM. et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 2017; 174: 990-998
• 130 Goodwin FK. Anticonvulsant therapy and suicide risk in affective disorders. J Clin Psychiatry 1999; 60: 89-93
• 131 Kovacsics CE, Gottesman II, Gould TD. Lithium’s antisuicidal efficacy: Elucidation of neurobiological targets using endophenotype strategies. Ann Rev Pharmacol Tox 2009; 49: 175-198
• 132 Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: A mini-review. Neuropsychobiology 2010; 62: 43-49
• 133 Swann AC. Mixed features: Evolution of the concept past and current definitions and future prospects. CNS Spectr 2017; 22: 161-169
• 134 Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect?. Pharmacopsychiatry 2001; 34: 132-136
• 135 Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharmaceut Design 2006; 12: 2985-2992
• 136 Lewitzka U, Severus E, Bauer R. et al The suicide prevention effect of lithium: More than 20 years of evidence – a narrative review. Int J Bipolar Disord 2015; 3: 32